



PTO/SB/08A (10-01)


Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/714,568
				Filing Date	November 13, 2004
				First Named Inventor	Hofgen, Norbert
				Art Unit	1626
				Examiner Name	To be assigned G. Shameem
Sheet	1	of	2	Attorney Docket Number	HUBR-1253

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
[Signature]	AA	5,567,711	10-22-1996	Abbott Laboratories	
	AB	6,008,231	12-28-1999	ASTA Medica Aktiengesellschaft	
	AC	6,251,923 B1	06-26-2001	Arzneimittelwerk Dresden GmbH	
	AD	6,545,025 B2	04-08-2003	Arzneimittelwerk Dresden GmbH	
	AE	6,545,158 B2	04-08-2003	Arzneimittelwerk Dresden GmbH	
	AF	6,602,890 B2	08-05-2003	Arzneimittelwerk Dresden GmbH	
	AG	6,613,794 B2	09-02-2003	Arzneimittelwerk Dresden GmbH	
	AH	US 2002/0111351 A1	08-15-2002	Hofgen et al.	
	AI	US 2002/0115651 A1	08-22-2002	Hofgen et al.	
	AJ	US 2002/0119971 A1	08-29-2002	Hofgen et al.	
[Signature]	AK	US 2002/0137745 A1	09-26-2002	Hofgen et al.	
	AL	US 2003/0134876 A1	07-17-2003	Hofgen et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	AM	DE 100 53 275 A1	05-02-2002	Hofgen et al.		
	AN	DE 198 18 964 A1	11-04-1999	Hofgen et al.		
	AO	WO 2004/000832	12-31-2003	AKZO NOBEL N.V.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
[Signature]	AP	BARNES, Chronic obstructive pulmonary disease: new opportunities for drug development, TIPS - October 1998 (Vol. 19)	
[Signature]	AQ	BEAVO, et al., Multiple Cyclic Nucleotide Phosphodiesterases, Molecular Pharmacology, 46, 1994	
[Signature]	AR	BERTACCINI, et al., Synthesis and pharmacological activity of some 5-methoxyidole derivatives occurring in nature, Il Farmaco, N. 4, April 1967	
[Signature]	AS	GROSSMAN, The value of antibiotics and the outcomes of antibiotic therapy in exacerbations of COPD, CHEST, 113/4, 1998	
[Signature]	AT	HALL, Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses, J. Clin. Pharmac., 1993, 35	
[Signature]	AU	JERSMANN, et al., Enhancement of lipopolysaccharide-induced neutrophil oxygen radical production by tumor necrosis factor alpha, Infection and Immunity, April 1998	
[Signature]	AV	KARLSSON, et al., Phosphodiesterase 4 inhibitors for the treatment of asthma, Ashley Publication Ltd., 1997	
Examiner Signature	[Signature]		Date Considered 4/11/06



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/714,568
				Filing Date	November 13, 2004
				First Named Inventor	Hofgen, Norbert
				Art Unit	1626
				Examiner Name	To be assigned G Shannen
Sheet	2	of	2	Attorney Docket Number	HUBR-1253

<input checked="" type="checkbox"/>	AW	KUMMER, Asthma und COPD, Atemw.-Lungenkrkh., Jahrgang 20, No. 5, 1994	
<input checked="" type="checkbox"/>	AX	NORMAN, COPD: new developments and therapeutic opportunities, Drugs News Prospect 11(7), September 1998	
<input checked="" type="checkbox"/>	AY	RENNARD, COPD: overview of definitions, epidemiology, and factors influencing its development, CHEST, 113/4, April 1998	
<input checked="" type="checkbox"/>	AZ	SCHUDT, et al., Phosphodiesterase inhibitors, Academic Press, 1996	
<input checked="" type="checkbox"/>	BA	THORPHY, et al., Phosphodiesterase inhibitors: new opportunities for the treatment of asthma, Thorax, 1991	
<input checked="" type="checkbox"/>	BB	THORPHY, et al., Novel phosphodiesterase inhibitors for the therapy of asthma, DN&P 6(4), May 1993	
<input checked="" type="checkbox"/>	BC	WENISCH, et al., Effect of pentoxifylline in vitro on neutrophil reactive oxygen production and phagocytic ability assessed by flow cytometry, Clin. Drug Invest., February 1997	
<input checked="" type="checkbox"/>	BD	WILSON, The role of infection in COPD, CHEST, 1998	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	9/11/08
-----------------------	--	--------------------	---------